Enlivex Therapeutics

Cell therapy / immunology

ENLV · Nasdaq · Israel

Share price · ENLV

$1.20-23.12 (-95.07%) 3M

close as of 2026-11-18 · 24h delayed · vol 40K (0.3x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when ENLV's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 2 Nov 2026-20.8%
  2. 30 Oct 2026-29.9%
  3. 30 Jul 2026-13.3%
  4. 28 Jul 2026-47.4%
  5. 16 Jul 2026-18.7%

    Nothing announced by ENLV that day or the session before.

  6. 14 Jul 2026-9.3%
  7. 27 May 2026+14.3%
  8. 13 Apr 2026-12.8%

    Nothing announced by ENLV that day or the session before.

  9. 8 Apr 2026+12.0%
  10. 30 Mar 2026-14.3%

Share of unusual movement by asset

For each asset, the share of ENLV's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Allocetra
events and moves
4shown from 8 days
Assets with fewer than 8 event days, together—7%
Other company news (earnings, financing, releases naming no asset)—41%
Sessions with no dated event—52%

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 2
Macrophage reprogrammingCell therapy
Osteoarthritis

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
February 2027 (1)
AllocetraPhase 2Primary Knee Osteoarthritis
Est. primary completion 2027-02 · NCT07580716 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

18 August 2025Topline resultAllocetraPhase IIa stage of ENX-CL-05-001 (NCT06233474): positive three-month topline data in knee osteoarthritis
Enlivex Therapeutics · Source ↗

Financial reports

Quarterly & interim (4)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-Q2—$2.1M$2.4M+ <$0.1M short-term inv.$1.9Mreport ↗

For the period ended June 30, 2025, Enlivex Therapeutics reported no disclosed revenue. R&D spend was $2.14M, up 7% YoY from $2M, while cash and equivalents stood at $2.35M. The company reported a net loss of $1.87M, corresponding to a quarterly net burn of $1.87M.

The accompanying proxy materials disclose an annual general meeting scheduled for November 10, 2025, with proposals to elect five directors, increase authorized share capital from NIS 18,000,000 divided into 45,000,000 ordinary shares to NIS 200,000,000 divided into 500,000,000 ordinary shares, and reappoint Yarel & Partners as independent registered public accountants. Management will also review the audited consolidated financial statements for the year ended December 31, 2024 at the meeting.

View 3 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-Q2—$2.0M$4.2M+ $0.2M short-term inv.$3.1Mreport ↗
2023-Q2—$5.0M$3.9M+ $25M short-term inv.$6.8Mreport ↗
2022-Q2—$4.1M$21M$9.9Mreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$9.2M$2.4M+ $3.9M short-term inv.—-$10M operating cash flowreport ↗
View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$11M$3.7M+ $0.2M short-term inv.$3.8M-$13M operating cash flowreport ↗
2023-FY—$19M$1.2M+ $5.1M short-term inv.$7.3M-$24M operating cash flowreport ↗
2022-FY—$19M$50M+ $0.3M short-term inv.$7.8M-$24M operating cash flowreport ↗
2021-FY—$13M$12M+ $63M short-term inv.$3.6M-$18M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

No Form 4 transactions on file in the stored window.

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 35 reporting institutions held 3.6M shares ($3.3M, 21.6% of shares outstanding).

#InstitutionSharesValue
1Diametric Capital, LP1,483,178$1.4M
2ARK Investment Management LLC628,310$584K
3PRELUDE CAPITAL MANAGEMENT, LLC225,738$210K
4TWO SIGMA INVESTMENTS, LP146,412$136K
5UBS Group AG138,328$129K
6BANK OF AMERICA CORP /DE/130,401$121K
7RENAISSANCE TECHNOLOGIES LLC128,192$119K
8JPMORGAN CHASE & CO125,948$113K
9GOLDMAN SACHS GROUP INC102,093$95K
10XTX Topco Ltd100,362$93K
11MORGAN STANLEY98,333$91K
12GEODE CAPITAL MANAGEMENT, LLC80,560$75K
13Invesco Ltd.61,654$57K
14CITADEL ADVISORS LLC27,965$26K
15TWO SIGMA SECURITIES, LLC20,044$19K